ACTRN12610000834055已完成2 期
An open-label, phase 2, single centre, randomised, crossover design bioequivalence study of AndroForte (R) 5 Compared With Testogel (R) 1% in Hypogonadal Men
awley Pharmaceuticals0 个研究点目标入组 16 人开始时间: 2010年10月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- Male
入选标准
- •Established androgen deficiency (primary or secondary) (including newly diagnosed persons) requiring androgen replacement therapy as determined by current Pharmaceutical Benefit Scheme (PBS) guidelines (laboratory results demonstrating that Australian guidelines have been met must be available for review)
- •Established androgen deficiency (primary or secondary) and currently receiving androgen replacement therapy (at an equivalent dose as outlined in this protocol) and willing to withdraw from current androgen replacement therapy and observe the necessary washout period prior to entering the study as outlined below:
- •- 7 days for transdermal testosterone or oral testosterone undecanoate
- •- 6-12 weeks for intramuscular injections of testosterone esters
- •- 6 months since last dose for subcutaneous testosterone pellets or testosterone undecanoate
排除标准
- •* Untreated obstructive sleep apnoea as determined by the Berlin Sleep Apnoea questionnaire
- •* Clinically significant non-malignant disease including, active clinically significant infection (requiring systemic antibiotics), cerebrovascular event or transient ischemic attack within 12 months prior to randomisation or major surgery within 3 months of randomisation
- •* Active cardiac disease defined as one or more of the following
- •- New York Heart Association functional classification of heart failure of greater than or equal to 2 or symptomatic angina
- •- Uncontrolled arrhythmias, or arrhythmias deemed clinically significant by the investigator
- •- Myocardial infarction, cardiac stenting or angioplasty in past 6 months
- •* Prior history of prostate cancer or other malignancy, which could affect compliance with the protocol or interpretation of study results. Cancer(s) treated with curative intent (including non-melanoma skin cancer) are eligible if disease-free for at least 2 years.
- •* Any form of respiratory failure requiring oxygen supplementation
- •* Evidence of a significant medical illness, abnormal laboratory finding or adverse event from prior androgen replacement therapy that would, in the investigators’ judgment, make the participant inappropriate for this study
- •* Receipt of therapy with another investigational drug within 4 weeks of Day 1 or current enrolment in another clinical trial
- •* Current smoker or past smoker who has ceased smoking within the past year
- •* Elevated blood pressure (greater than or equal to 140/90mmHg) at screening or a diagnosis of hypertension unless on stable therapy for at least 3 months and currently normotensive
- •* History of mental illness (requiring ongoing psychotropic medications)
- •* Active substance abuse
- •* Known to be human immunodeficiency virus (HIV) or hepatitis B surface antigen positive
- •* Planned elective surgery within 1 month of randomisation or during the study period
- •* Generalised skin disease on the abdomen that may be affected by or affect testosterone absorption at the site of transdermal absorption – e.g. psoriasis
- •* Body Mass Index (BMI) of less than 18 kg/m2 or more than 35 kg/m2 as either extreme may result in hypogonadism responsive to normalisation of weight
- •* Currently on medications, herbal remedies or vitamins/juices (e.g. grapefruit juice) known to
- •- Be strong inducers/ inhibitors of Cytochrome 3A4 (CYP 3A4)
- •- Affect the production (e.g. opiates, gonadotropin releasing hormone (GnRH) agonists) or action (e.g. spironolactone) of androgens
- •- Affect the production of SHBG (e.g. thyroxine, insulin, growth hormone, antiepileptics), unless the dose has been stable for at least 3 months and will remain so.
- •* Dementia or altered cognitive function that would interfere with the participant’s safety or compliance to the study procedures
- •* Use of topical salves or topical steroids to abdomen within past 7 days
- •* Participants unwilling to adhere to the guidelines in regard to intimate contact post application
- •* Known allergy to almonds
- •* Participants experiencing severe voiding symptoms as identified on the International Prostate Symptom Score (IPSS) questionnaire
- •* Men who are able to father a child who are unwilling to use an acceptable method of contraception during the trial
研究者
相似试验
已完成
2 期
An open-label, phase 2, single centre, randomised, crossover pharmacokinetic study assessing two application areas of 0.5ml (5mg) of a testosterone 1% cream, ANDROFEME(Registered trademark) in healthy postmenopausal womeAndrogen deficiency in postmenopausal womenReproductive Health and Childbirth - Other reproductive health and childbirth disordersACTRN12614000962639awley Pharmaceuticals20
进行中（未招募）
不适用
A randomized, open label, single center, phase IIa controlled trial to assess tolerability, safety and effect of treatment with deferasirox plus standard antiviral therapy versus standard antiviral therapy in chronic hepatitis C patients na?ve to treatment with interferon and/or ribavirin - NDChronic hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912EUCTR2009-012344-17-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
已完成
2 期
Safety and immune response of the malaria vaccine, R21/Matrix-M™, in Thai adultsMalaria vaccine in healthy volunteersISRCTN57717892niversity of Oxford127
进行中（未招募）
1 期
A single center, phase II, open label randomized clinical trial to evaluate the inhibition of ovulation of three prolonged release formulations containing a combination of gestagen and oestrogen versus a conventional flexible regimen contraceptive in 100 healthy women.EUCTR2016-003830-26-DEExeltis France100
进行中（未招募）
1 期
A Phase II, Single Centre, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy InfantsEUCTR2006-003476-35-GBovartis Vaccines and Diagnostics S.r.l216